Cargando…

1400. Pretomanid in the Treatment of Patients with Tuberculosis in the United States: the Bedaquiline, Pretomanid and Linezolid (BPaL) Accelerated Monitoring (BAM) Project

BACKGROUND: In August 2019 the U.S. FDA approved pretomanid as part of a 6-month all-oral BPaL (bedaquiline, pretomanid, and linezolid) regimen for treating pulmonary extensively drug-resistant (XDR) or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB). In the study s...

Descripción completa

Detalles Bibliográficos
Autores principales: Goswami, Neela, Peddareddy, Lakshmi Praveena, Jereb, John, Semidey, Angel Colon, Darnall, Elaine, Macias, Patricia, Jasuja, Supriya, Landers, Karen, Dasgupta, Shom, Oxtoby, Margaret, Spitters, Christopher, Dov, Lana, Narita, Masa, DaSilva, Malini, Cropper, Tracina, Gullickson, Cricket, Ashkin, David, Haley, Connie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643925/
http://dx.doi.org/10.1093/ofid/ofab466.1592